<DOC>
	<DOC>NCT00997074</DOC>
	<brief_summary>In the current study, we want to evaluate the prophylactic use of ibuprofen versus a placebo for medical abortion by mifepristone and misoprostol, at a gestational age of up to 7 weeks, in regard to the effect on pain relief and the overall procedure success. expected results: The prophylactic use of NSAIDs could offer significant pain relief and thereby a reduction in the need for additional pain relievers compared to the placebo, without interfering with the outcome of medical abortion</brief_summary>
	<brief_title>Efficacy Study of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion</brief_title>
	<detailed_description />
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Good general health Pregnancy of up to 7 weeks gestation. Approval from the Ministry of Health committee for termination of pregnancy after an intrauterine pregnancy was demonstrated by an ultrasound exam. Subjects that provided informed consent and agree to comply with all study procedures. Known allergy to mifepristone, misoprostol, paracetamol or NSAIDs. Severe anemia. Drug or alcohol abuse Known abnormal liver function (liver function tests greater than 1.5 times upper range of normal). Known abnormal renal function (serum creatinine &gt; 1.5 mg/dl). Abnormal blood tests Exclusionary health problems contraindicating mifepristone included adrenal disease; sickle cell anemia; severe liver, respiratory, or renal disease; and blood clotting defect. Chronic disease Patient is participating currently in another clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>pain after abortion</keyword>
	<keyword>abortion</keyword>
</DOC>